Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OPKO Health Inc Completes Acquisition Of PROLOR Biotech


Thursday, 29 Aug 2013 12:22pm EDT 

OPKO Health Inc announced the completion of the acquisition of PROLOR by OPKO. Pursuant to the acquisition, stockholders of PROLOR will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. Barrington Research Associates, Inc., acted as the financial advisor to OPKO in connection with the transaction. Jefferies LLC acted as financial advisor to PROLOR in connection with the transaction, and Oppenheimer & Co. provided a fairness opinion to PROLOR's Strategic Alternatives Committee. Akerman Senterfitt acted as U.S. legal advisor to OPKO and Pearl Cohen Zedek Latzer Baratz acted as OPKO's legal advisor in Israel. DLA Piper LLP (US) acted as legal advisor to PROLOR's Strategic Alternatives Committee, Greenberg Traurig, P.A. acted as U.S. legal advisor to PROLOR and Gornitzky & Co. acted as PROLOR's legal advisor in Israel. Further terms of the transaction were not disclosed. 

Company Quote

9.6
0.14 +1.48%
19 Dec 2014